Carl Barrett

1.1k total citations
25 papers, 252 citations indexed

About

Carl Barrett is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Carl Barrett has authored 25 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Carl Barrett's work include Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Carl Barrett is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Carl Barrett collaborates with scholars based in United States, United Kingdom and Japan. Carl Barrett's co-authors include Kathleen D. Danenberg, Darlene Dixon, Johnathan M. Lancaster, Heinz‐Josef Lenz, Mizutomo Azuma, John I. Risinger, Dongyun Yang, Alicia B. Moore, Stanley J. Robboy and Joseph K. Haseman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Carl Barrett

21 papers receiving 244 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carl Barrett United States	7	126	80	73	49	48	25	252
Floriana Camarda Italy	7	136 1.1×	89 1.1×	46 0.6×	40 0.8×	44 0.9×	27	236
Irene Papaspyrou Greece	9	106 0.8×	96 1.2×	50 0.7×	54 1.1×	65 1.4×	13	262
Ajit Paintal United States	12	99 0.8×	91 1.1×	128 1.8×	55 1.1×	55 1.1×	24	333
Graziana Ronzino Italy	6	116 0.9×	70 0.9×	38 0.5×	51 1.0×	48 1.0×	22	237
Valerie Heong Singapore	10	135 1.1×	107 1.3×	32 0.4×	27 0.6×	48 1.0×	25	243
Susan Valmadre Australia	7	108 0.9×	90 1.1×	38 0.5×	69 1.4×	70 1.5×	11	319
Clare Bartos United Kingdom	9	74 0.6×	92 1.1×	39 0.5×	66 1.3×	64 1.3×	13	246
M K Heatley United Kingdom	11	83 0.7×	62 0.8×	31 0.4×	80 1.6×	36 0.8×	17	258
Apostolos C Ziogas Greece	5	148 1.2×	122 1.5×	42 0.6×	45 0.9×	50 1.0×	32	315
Jodi A. McKenzie United States	8	121 1.0×	155 1.9×	73 1.0×	27 0.6×	54 1.1×	30	302

Countries citing papers authored by Carl Barrett

Since Specialization

Citations

This map shows the geographic impact of Carl Barrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Barrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Barrett more than expected).

Fields of papers citing papers by Carl Barrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Barrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Barrett. The network helps show where Carl Barrett may publish in the future.

Co-authorship network of co-authors of Carl Barrett

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Barrett. A scholar is included among the top collaborators of Carl Barrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Barrett. Carl Barrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravi, Praful, Jenna I. Wurster, Corrie Painter, et al.. (2024). Determination of tumor PSMA expression and lutetium-PSMA response in men with prostate cancer using a novel epigenomic liquid biopsy platform. 5. 100193–100193.

Gray, Jhanelle E., Aleksandra Markovets, Thanyanan Reungwetwattana, et al.. (2024). Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 19(11). 1525–1538. 5 indexed citations

Stetson, Daniel, Gregory T. Jones, Giovanni Marsico, et al.. (2023). Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Cancer Research. 83(7_Supplement). 3384–3384. 1 indexed citations

Schick, Markus, Thomas Kunzke, Thomas Padel, et al.. (2022). 583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients. Regular and Young Investigator Award Abstracts. A610–A610. 1 indexed citations

Kurokawa, Cheyne, Abhisek Mitra, Elena Galvani, et al.. (2022). 835 AZD4820 oncolytic vaccinia virus encoding IL-12 mediates anti-tumor activity through oncolysis and tumor-specific immunity. Regular and Young Investigator Award Abstracts. A872–A872.

Hernández, M., Benjamin Besse, Mark M. Awad, et al.. (2021). P16.07 Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON). Journal of Thoracic Oncology. 16(3). S350–S351. 2 indexed citations

Tan, Tze Heng, Sriram Sridhar, Helen K. Angell, et al.. (2020). 269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer. SHILAP Revista de lepidopterología. A165–A166. 1 indexed citations

Chandra, Dinesh, Christine M. Barbon, Alexandra Borodovsky, et al.. (2020). Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells. Cancer Immunology Research. 8(3_Supplement). A87–A87. 2 indexed citations

O’Connor, Lenka Oplustil, Grégory Hamm, Stephanie Ling, et al.. (2020). Abstract 6168: Characterization of ATM inhibitor (AZD1390) distribution and pharmacodynamic changes in brain and glioblastoma in preclinical models to inform on mechanism of action. Cancer Research. 80(16_Supplement). 6168–6168. 1 indexed citations

10.

Overend, Philip, Ryan J. Hartmaier, Aleksandra Markovets, et al.. (2020). Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC). Cancer Research. 80(16_Supplement). CT024–CT024.

11.

Barbon, Christine M., Alexandra Borodovsky, Yanjun Wang, et al.. (2019). Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells. Cancer Research. 79(13_Supplement). LB–192. 3 indexed citations

12.

Cho, Byoung Chul, Changdong Zhou, Fumio Imamura, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. ix177–ix177. 28 indexed citations

13.

Oxnard, Geoffrey R., Kenneth S. Thress, Ryan S. Alden, et al.. (2016). 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. Journal of Thoracic Oncology. 11(4). S154–S154. 11 indexed citations

14.

Yeh, Tammie C., Vivien N. Jacobs, Joseph Geradts, et al.. (2016). 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1). Journal of Thoracic Oncology. 11(4). S80–S81. 7 indexed citations

15.

Greenawalt, Danielle M., et al.. (2015). Abstract B51: Tumor genetic shift post standard of care therapy. Molecular Cancer Therapeutics. 14(12_Supplement_2). B51–B51.

16.

Chenna, Ahmed, Weidong Huang, Gayle Marshall, et al.. (2013). Abstract 3029: Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2/ErbB2 levels using proximity-based immunoassays.. Cancer Research. 73(8_Supplement). 3029–3029. 3 indexed citations

17.

Yuan, Ziqiang, Asha Adem, Rula C. Geha, et al.. (2012). Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity. Cancer Gene Therapy. 20(1). 46–56. 29 indexed citations

18.

Grimminger, Peter, Carl Barrett, David Lebwohl, et al.. (2011). TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. The Pharmacogenomics Journal. 12(5). 404–411. 33 indexed citations

19.

Azuma, Mizutomo, M. Shi, Christian Jacques, et al.. (2006). Tumor VEGFA gene expression is associated with serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 24(18_suppl). 3530–3530. 5 indexed citations

20.

Dixon, Darlene, Gordon P. Flake, Alicia B. Moore, et al.. (2002). Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 441(1). 53–62. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact